Two of the most impactful biotech companies in Delaware are now partnering on the future of cancer treatments.
Incyte, a global oncology company with a headquarters in Wilmington, and Agilent, a California-based global diagnostics firm with a large Delaware presence, will collaborate on companion diagnostics (CDx) development programs.
Companion diagnostics is a test that uses prescreening to create a group of patients with the highest possible response rate to targeted therapies while screening out patients who are likely to react negatively to the treatment.
Agilent has long played a role in companion diagnostics: 25 years ago, Dako, which Hewlettt-Packard spinoff Agilent acquired in 2012, got approval for the HercepTest for breast cancer patients in partnership with a company called Genentech.
“Ultimately, this kicked off the world of companion diagnostics,” said Paul Beresford, vice president and general manager of Agilent’s Companion Diagnostics Division. Dako will be used for companion diagnostics with Incyte.
“Typically a pharma will come to us with one particular program, and that’s the case with Incyte,” said Beresford. “We put a partnership in place that will help them across our whole portfolio, so as their drugs mature through their development, we have the infrastructure in place contractually and relationship-wise to then catch those opportunities.”
In short, they can offer newly-developed diagnostic tools to be used as part of Incyte’s development of oncology treatments so that they’re used on patients most likely to benefit from it.
The partnership shines a spotlight on one of the big Delaware technology stories of the last year: The state is coming into its own as a major part of the Greater Philadelphia Region Precision Medicine Tech Hub, one of several regional ecosystems identified by the Economic Development Administration’s Tech Hubs program.
“These sort of hubs of innovation bring together companies that have a common purpose,” Beresford said. “If you think of Boston’s, San Diego’s and now, potentially, Delaware’s biotech communities, it’s a critical mass where you get companies like Agilent and Incyte coming together.”
Collaboration plays a big part in any tech ecosystem, Beresford said, and co-development is a good example of that.
“Definitely an important part of ecosystems, as they form across the country, is that they bring these types of companies together, and that ultimately benefits medicine,” he said. “You bring the best companies or people together, and ultimately it ends up resulting in some incredible developments.”
Before you go...
Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.
3 ways to support our work:- Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
- Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
- Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!